Rosemarie Lajara is an Endocrinology/Metabolic physician affiliated with Plano Cancer Institute. OpenAlex indexes 33 publications with 1,041 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1708 Coit Rd
Suite 100
Plano, TX 750755024
Telephone
832-237-3500Registry record last updated 21 Jul 2022.
Industry payments
44 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year2025146 payments$100,923openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year202556 payments$44,092openpaymentsdata.cms.gov ↗
- Sequel Med Tech, LLCProgram year202537 payments$31,000openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
73.3%GLP-1 receptor agonist22.1%Ozempic53%Mounjaro32%Trulicity16%Part D<11 patientsInsulin Analog21.5%Toujeo Max Solostar20%Humalog Kwikpen U-10013%Lantus Solostar13%Toujeo Solostar11%Tresiba Flextouch U-10011%Soliqua 100-3310%Humalog8%Insulin Lispro Kwikpen U-1007%Novolog6%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
13.8%l-Thyroxine13.8%Levothyroxine Sodium81%Synthroid19%Part D≥36 patientsCardiovascular
11.9%Statin6.6%Rosuvastatin Calcium47%Atorvastatin Calcium40%Pravastatin Sodium13%Part D<11 patientsACE inhibitor2.2%Lisinopril100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Parita Bhuva, MD
Plano Cancer Institute
Seemal Desai, MD
Plano Cancer Institute
Crescens Pellecchia, DO
Plano Cancer Institute
Ahmad Zankar, MD
Plano Cancer Institute
Jens J. Holst
University of Copenhagen
Victor Montori, MD
Mayo Clinic
Daniel J. Drucker
University of Toronto
Kenneth Cusi, MD
University of Florida College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”